Light-chain (AL) amyloidosis is a rare systemic disorder characterized by the deposition of misfolded protein aggregates into various organs such as the heart, kidney, liver, or gastrointestinal tract. To date, there is no standard treatment approach for previously treated AL amyloidosis. Moreover, while daratumumab, cyclophosphamide, bortezomib, dexamethasone (Dara-CyBorD) is now considered the standard-of-care in newly diagnosed AL amyloidosis [1], the use of bortezomib may be limited by pre-existing disease-related sensorimotor polyneuropathy. Thus, there remains a continued need to explore novel therapeutic approaches in AL amyloidosis with the goal of optimizing efficacy and tolerability.
